Systematic literature review of the epidemiology of advanced prostate cancer and associated HRR gene alterations.
Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S.
Journal of Urology (2020)
Targeted literature review (TLR) of the real-world treatment patterns and outcomes among mCRPC patients in EU5, Japan and Australia.
Oliver L, Ghate S, Shui I, Gayle A, Wong O Y, Kim J, Payne S, Shore N.
Poster presentation during PROSCA (Global congress on prostate cancer) 2020
Three-year analysis of healthcare utilization in patients with low-grade upper tract urothelial cancer (LG-UTUC) treated with ureteroscopic management or RNU.
Thacker K, Smith G, Begum N, Kamgar F, Pilossoph L, Oliver L, Moore W, Misir S, Mikhelashvili T.
Poster presented during AMCP Nexus 2020 Virtual Conference
Modelling the resource utilisation difference of using subcutaneous and intravenous administration of Rituximab within chemotherapy for the treatment of B-cell lymphoma.
Hughes R, Swales O, Lucherini S.
Value in Health, Vol. 23, Supplement 1, S35-S36, MAY 01, 2020
Targeted literature review (TLR) of the real-world treatment patterns and outcomes among MCRPC patients in the US.
Shore N, Oliver L, Shui I, Gayle A, Wong O Y, Kim J, Payne S, Amin S, Ghate S.
Value in Health, Vol. 23, Supplement 1, S23, May 01 2020
Understanding the Economic Burden of Treating Low-Grade Upper Tract Urothelial Cancer in the United States.
Thacker K, Raman J, McLean T, Said J, Oliver L, Gore J.
Urology Practice. 2020 Jun 9:10-97.
Review of the real-world prevalence of a range of prostate cancer (PC) types (mHSPC, nmCRPC, mCRPC), and gene alterations in prostate cancer.
Shore N, Oliver L, Shui I, Gayle A, Wong O Y, Kim J, Payne S, Ghate S.
Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 229-229.
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukaemia in a Canadian setting
Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J
Appl Health Econ Health Policy (2019)
Economic evaluations of subcutaneously administered oncology therapies: A health technology assessment (HTA) landscape review
Wu E, Schenkel B, Povsic M, Wyn R, Hernani M, Kornalska K
Poster presented at ISPOR, 20-22 May 2019, New Orleans, USA
Budget projections and health impact of the PD-1/PD-L1 inhibitors to inform budget planning – the experience from four European countries
Roediger A, van Bavel J, Pellissier J, Lucherini S, Davies N, Okhuoya P, Rachev B
Poster presenter at the HTAi conference, 15-19 June 2019, Cologne, Germany
Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)
Povsic M, Enstone A, Wyn R, Kornalska K, Penrod JR, Yuan Y
Poster presented at ISPOR, 12-14 November 2018, Barcelona, Spain
Health status in patients with SCLC treated with nivolumab alone or combined with ipilimumab: CheckMate 032Understanding the patient perspective of small cell lung cancer
Rydén A, Ollis S, Love E, Shields AL, Jiang H, Dennis PA
Poster presented at the 8th European Lung Cancer Congress, Geneva, Switzerland 11-14 April 2018
Ardizzoni A, Farago AF, Atmaca A, Calvo E, Taylor F, Bennett B, Selvaggi G, Pieters A, Penrod JR, Yuan Y, Ross Camidge D
Poster presented at the 18th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC); Yokohama, Japan, 15-18 October, 2017
The humanistic burden of small cell lung cancer (SCLC): A systematic review of health-related quality of life (HRQoL) literature
Bennett B M, Wells J R, Panter C, Yuan Y, Penrod J R.
Front Pharmacol. 2017 Jun 15;8:339.
Understanding key symptoms, side effects and impacts of HR+ and HER2- advanced breast cancer: Qualitative patient interviews
Cella D, Dillard S, Galipeau N, Higgins S, Klooster B, Krohe M, Revicki D, Tang D, Small T
24th Annual Conference of the International Society for Quality of Life Research
Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142
Overman M, Kamble S, Moss R, Taylor F, Maglinte G, Shaw J, Cocks K, Mann E, Yip C, Andre T
Poster presented at the ESMO 19th World Congress on Gastrointestinal Cancer, 28 June 2017
Understanding the symptoms, impacts and treatment side-effects of advanced bladder cancer from the perspective of the literature, clinicians, and patients
Degboe A, Banderas B, Halling K, Mazar I, Mann E
Poster session presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Boston, MA USA, 20-24 May 2017
Association of health-related quality of life and healthcare resource utilization in CheckMate 141, a phase 3 study of nivolumab versus investigator’s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
DeRosa M, Cocks K, Korytowsky B, Contente M, Taylor F, Shaw JW
Poster submitted to the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Glasgow, Scotland. 4-8 November.
Analyses of healthcare resource use (HCRU) in Checkmate 141, a phase III study of nivolumab versus therapy of investigator’s choice (IC) in patients with recurrent or metastatic (R/M) platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)
DeRosa M, Cocks K, Taylor F, Bobiak S, Juarez Garcia A, Shaw JW.
Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 22nd Annual International Meeting, Boston, US, 20-24 May 2017
Effect of nivolumab on patient-reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation: Results from the multicohort phase 2 CheckMate 205 study
Engert A, Taylor F, Bennett B, Chen C, Cocks K, McDonald J, Mann E, Sacchi M, Cella D
Presented at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
Nivolumab versus investigator’s choice therapy among patients with human papillomavirus-associated squamous cell carcinoma of the head and neck: Updated results from CheckMate 141
Gillison ML, Harrington K, Ferris RL, Guigay J, Blumenschein G, Jr., Fayette J, Colevas AD, Kiyota N, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Saba NF
AHNS Annual Meeting
Living with the burden of relapse in multiple myeloma from the patient and physician perspective
Hulin C, Hansen T, Heron L, Pughe R, Streetly M, Plate A, Perkins S, Morgan K, Tinel A, Rodrigues F, Ramasamy K
Leukaemia Research 59 (2017) 75-84
Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial
Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J
Lancet Oncology
Understanding key symptoms, side effects and impacts of HR+ and HER2- advanced breast cancer: Literature review and expert interviews
Krohe M, Tolley C, Higgins S, Cella D, Revicki D, Small T, Tang D
Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 22nd Annual International Meeting, Boston, MA USA, 20-24 May 2017
Market access challenges to PD-1 immunotherapies: Lessons from NICE
McLean T, Tavella F, Heron L
Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 20th Annual European Congress, Glasgow, Scotland, 4-8 November 2017
Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275
Necchi A, Grimm M, Retz M, Arranz JA, Bracarda S, Bedke J, Baron A, Sharma P, Galsky MD, Vaena D, Kalinka-Warzocha E, Cwikiel M, Pal SK, Morales-Barrera R, Taylor F, Gooden KM, Plimack ER
American Society of Clinical Oncology
Assessing the comparability of paper and electronic versions of the EORTC QOL module for head and neck cancer: A qualitative study
Norquist J, Chirovsky D, Munshi T, Tolley C, Panter C, Gater A.
JMIR Cancer. 2017 May 12;3(1):e7
Patient-reported outcomes in DNA mismatch repair deficient/ microsatellite instability-high metastatic colorectal cancer treated with nivolumab: CheckMate 142
Overman M, Kamble S, Moss RA, Taylor F, Maglinte GA, Shaw JW, Cocks K, Mann E, Yip C, André T
19th World Congress on Gastrointestinal Cancer
Predicting EQ-5D utility index scores for gastric cancer patients in Japan: A preliminary model
Pike J, Maglinte GA, Rider A, Cocks K, Taylor F, Contente M, Calvo E
Poster submitted to the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Glasgow, Scotland. 4-8 November.
Validation of two cancer care plan communication tools
Staunton H, Yagnik S, Williamson N, Spencer H, Kaur S, Bennett B, Donelson S, Jagun D, Goertz H, Stein A
Presented at the ASCO Quality of Care Symposium, March 3rd-4th, Florida, 2017
Working together to foster better patient-centred cancer care: “Setting international standards in analysing patient-reported outcomes and quality of life endpoints data”
Oliver K, Peuters C, on behalf of the SISAQOL Consortium
Patient Advocacy Lounge at the British Neuro-Oncology Society (BNOS) annual conference, 21 June 2017
Health-related quality of life results from the phase III CheckMate 067 study
Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV
European Journal of Cancer
A quality-adjusted time without symptoms of disease and toxicity (Q-TWIST) analysis comparing nivolumab and therapy of investigator’s choice (IC) in patients with recurrent or metastatic (R/M) platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) (CheckMate 141)
Simpson S, Cocks K, Korytowski B, Contente M, DeRosa M, Taylor F, Shaw JW.
Poster submitted to the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Glasgow, Scotland. 4-8 November.
Cognitive debriefing of the Advanced Systemic Mastocytosis Symptom Assessment Form (advSM-SAF)
Taylor F, Kreil S, Reiter A, Horny HP, Evans E, Mazar I, McNamara P, Boral A, Lamoureux RE, Shields A, Gotlib J
Poster session presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Boston, MA USA, 20-24 May 2017
A structured review of health utility measures and elicitation in advanced/metastatic breast cancer
Hao Y, Wolfram V, Cook J
ClinicoEconomics and Outcomes Research, vol. 2016:8, 293—303. June 2016
Developing a small cell lung cancer conceptual model to inform treatment outcome and assessment strategy decisions in clinical research
Ojo O, Shields AL, Morrissey L, Love E, Ollis S, Halling K, Rudell K
Poster to be presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Vienna, Austria, 29th Oct-2nd Nov 2016
Development and content validity of the advanced systemic mastocytosis symptom assessment form (ADVSM-SAF)
Mazar I, Evans E, Taylor F, Patki A, Ojo O, Lamoureux RE, Horny H, Reiter A, Gotlib J, Shields A
Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Vienna, Austria, 29th Oct-2nd Nov 2016
Clinical trial patient-reported outcomes data: Going beyond the label in oncology
Hao Y, Krohe M, Yaworsky A, Shields AL, Mazar I, Foley C, Globe D
Clinical Therapeutics (2016) 38(4):811-20.
Evidence for the content validity of the EORTC QLQ-C30: Review of existing data
Cocks K, Tolley C, Grant L, Wheelwright S, Tomaszewski K, Groenvold M, Bottomley A, Fitzsimmons D, Velikova G, Aaronson N, Johnson C
Qual Life Res 25, 1, ab303.4, 2016
Evidence for the content validity of the EORTC QLQ-C30: Review of existing data
Cocks K, Tolley C, Grant L, Wheelwright S, Tomaszewski K, Groenvold M, Bottomley A, Fitzsimmons D, Velikova G, Aaronson N, Johnson C
Podium presentation at International Society for Quality of Life Research (ISOQOL), 22 October 2016
Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057
Gralla RJ, Spigel DR, Bennett B, Taylor F, Penrod JR, DeRosa M, Reck M
Poster presented at: American Society of Clinical Oncology (ASCO), Chicago, Illinois, Jun 3-7, 2016
Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057
Gralla RJ, Spigel DR, Bennett B, Taylor F, Penrod JR, DeRosa M, Reck M
Journal of Clinical Oncology 34, 2016
Overall survival, health-related quality of life, and healthcare resource use: independent analyses from checkmate 025, a phase iii study of nivolumab versus everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma
Taylor F, Dastani H, Bennett B, DeRosa M, Berghorn E, Justin D
Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 21st Annual International Meeting, Washington DC, USA, 21-25 May 2016
Overall survival, health-related quality of life, and healthcare resource use: independent analyses from checkmate 025, a phase iii study of nivolumab versus everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma
Taylor F, Dastani H, Bennett B, DeRosa M, Berghorn E, Justin D
Value in Health, 19(3), A167
Patient subgroup analyses of quality of life outcomes in Checkmate 205. A phase 2 study of nivolumab in patients with classical Hodgkin lymphoma
Engert A, Taylor F, Bennett B, Hirji I, Cocks K, McDonald J, Mann E, Kato K, Cella D
Poster presented at: American Society of Hematology (ASH), San Diego California, December 3-6, 2016
Patient-reported outcomes for oncology product labeling in the US: Developing a rationale and navigating early challenges
Shields AL, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, Globe DG, Mehmud F
American Health & Drug Benefits, 9(4):188-197
Patient-reported outcomes in advanced breast cancer: A review of industry sponsored clinical trials
Krohe M, Hao Y, Lamoureux R, Galipeau N, Globe D, Foley C, Mazar I, Solomon J, Shields AL
Breast Cancer: Basic and Clinical Research, 10, 93-102
Patient-reported outcomes in advanced breast cancer: Inside the label and approval documents
Hao Y, Krohe M, Mazar I, Galipeau N, Foley C, Globe D, Turner-Bowker D, Shields AL
Expert Review of Quality of Life in Cancer Care (2016) 1(3): 197-205.
Patient-reported outcomes in metastatic breast cancer: A review of industry-sponsored clinical trials
Krohe M, Hao Y, Lamoureux RE, Galipeau N, Globe D, Foley C, Mazar I, Solomon J, Shields AL
Breast Cancer: Basic and Clinical Research (2016) 10: 93–102.
Patient-reported outcomes in oncology drug labeling in the United States: A framework for navigating early challenges
Shields AL, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, Globe DG, Mehmud F
American Health & Drug Benefits (2016) 9(4):188-197.
Patient-reported preferences for oral versus IV administration for the treatment of cancer: a review of the literature
Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, Shields AL
Patient Preference and Adherence, 10, 1609-1621
Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study
Cella D, Gruenwald V, Nathan PD, Doan J, Dastani H, Taylor F, Bennett BM, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ
Poster presented at: American Society of Clinical Oncology (ASCO), Chicago, Illinois, Jun 3-7, 2016
Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study
Cella D, Gruenwald V, Nathan PD, Doan J, Dastani H, Taylor F, Bennett BM, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ
Journal of Clinical Oncology 34, (suppl; abstr 4549)), 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
Cella D, Grünwald V, Nathan P, Doan J, Dastani H, Taylor F, Bennett BM, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ
The Lancet Oncology, 17(7):994-1003
Systematic review of the caregiver burden in melanoma and renal cell carcinoma within Europe
Farrington E, Zagorska A, Burnett J
Poster session presented at the Society for Melanoma Research (SMR) 13th International Congress, Boston, USA, 6-9 November 2016
The humanistic burden of small cell lung cancer: A systematic review of the health-related quality of life literature
Panter C, Bennett BM, Wells J, Yuan Y, Penrod JR
Poster presented at the European Society for Medical Oncology, Copenhagen Denmark Oct 7-11, 2016
The Quality of Survival (QoS): A concept framework to assist communication and decision-making about cancer care
Fallowfield L, Nadler E, Greaney M, Gater A, Subar M, Orsini L, Lyman GH
Presented at the ASCO Cancer Survivorship meeting, January 2016
The societal and humanistic burden of small cell lung cancer (SCLC): A systematic review of societal impact and health-related quality of life (HRQoL) literature
Enstone A, Panter C, Greaney MH, Bennett B, Penrod JR, Yuan Y
Value in Health, 19(7), A748
The societal and humanistic burden of small cell lung cancer (SCLC): A systematic review of societal impact and health-related quality of life (HRQoL) literature
Enstone A, Panter C, Greaney MH, Bennett B, Penrod JR, Yuan Y
Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Vienna, Austria, 29th Oct-2nd Nov 2016
Treatment patterns and clinical practices of advanced (stage IIIB and IV) non-small cell lung cancer (NSCLC) in Europe – A structured literature review
Brodowicz T, Niepel D, Booth E, Hernandez R, Braileanu G, Cawkwell M, Amelio J
Poster presented at the IASLC 17th World Conference on Lung Cancer, Vienna, Austria, December 4-7, 2016
The use of patient-reported outcomes in advanced breast cancer clinical trials: A review of the published literature
Turner-Bowker D, Hao Y, Foley C, Galipeau N, Mazar I, Krohe M, Globe D, Shields AL
Current Medical Research and Opinion (2016) 32 (10): 1709-1717. doi 10.1080/03007995.2016.1205005
Content validation and modification of the Treatment Satisfaction Questionnaire for Medication (TSQM) for use in breast cancer
DeBusk K, Maddux L, Turner-Bowker DM, Krupnick R, Skolas K, Patel S, Petersen J
Poster presentation at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
Development and content validity testing of the Patient-Reported Outcomes of Fatigue in Cancer (PROOF-C) symptom severity assessment (SSA)
Yaworsky A, Ojo O, Foley C, Bonthapally V, Ma E, Norquist J, Pompilus F, Pearson J, Park J, Arbuckle R
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 20th Annual International Congress, Philadelphia, PA, USA, 16-20 May 2015
Development and content validity testing of the patient-reported outcomes of fatigue in cancer (proof-c) symptom severity assessment (SSA)
Yaworsky A, Ojo O, Foley C, Bonthapally V, Ma E, Norquist J, Pompilus F, Pearson J, Park J, Arbuckle R
Value in Health, Volume 18, Issue 3, A210
Development, scoring and use of a patient questionnaire to measure the practical patient experience within oncology clinical trials
Manson S, Bonner N, Bennett B, Dewit O, Thomas G
DOI: 10.1200/jco.2015.33.15_suppl.e20567 Journal of Clinical Oncology 33, no. 15_suppl
Effect of nivolumab in combination with ipilimumab versus ipilimumab alone on quality of life in patients with treatment-naïve advanced melanoma: Results of a phase II study (CheckMate 069)
Abernethy AP, Postow MA, Chesney JA, Grossmann KF, Taylor F, Coon C, Gilloteau I, Dastani H, Gagnier P, Robert C
Poster session presented at: American Society of Clinical Oncology (ASCO), 51st Annual Meeting, Chicago, USA, 29 May-2 June 2015
Effect of nivolumab on quality of life in patients with treatment-naïve advanced melanoma: Results of a phase III study (CheckMate 066)
Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Waxman I, Abernethy AP
Poster session presented at: American Society of Clinical Oncology (ASCO), 51st Annual Meeting, Chicago, USA, 29 May-2 June 2015
Evaluation of disease-related symptoms in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel
Gralla RJ, Coon C, Taylor F, Penrod JR, DeRosa M, Dastani H, Orsini L, Reck M
Oral presentation presented at: World Conference on Lung Cancer, Denver, USA, 6-9 September 2015
Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
Reck M, Coon C, Taylor F, DeRosa M, Penrod JR, Dastani H, Orsini L, Gralla R
Oral presentation presented at: European Cancer Congress, Vienna, Austria, 25-29 September 2015
Health-related quality of life and health care resource use from a phase 3 study of nivolumab versus dacarbazine in patients with treatment-naïve advanced melanoma: CheckMate 066
Long GV, Taylor F, Gilloteau I, Dastani H, DeRosa M, Abernethy AP
Presented at the Society for Melanoma Research (SMR) 2015 Congress, San Francisco, CA, 18-21 November 2015
Health-related quality of life and treatment satisfaction among patients receiving novel anti-androgen therapies for the treatment of metastatic castrate-resistant prostate cancer (mCRPC)
Dearden L, Shalet N, Artenie C, Mills A, Gater A, Grant L, Jackson C
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 18th Annual European Congress, Milan, Italy, 7-11 November 2015
Patient reported outcomes from a phase 3 study of nivolumab alone or combined with ipilimumab (IPI) versus IPI in patients with advanced melanoma: CheckMate 067
Schadendorf D, Long GV, Larkin J, Wolchok J, Hodi S, Chiarion-Sileni V, Taylor F, Gilloteau I, Dastani HB, Walker D, Rollin L, Abernethy AP
Presented at the Society for Melanoma Research (SMR) 2015 Congress, San Francisco, CA, 18-21 November 2015
Qualitative interviews to provide in-depth understanding of the impact of non-small cell lung cancer (NSCLC) and its treatment on of the lives of patients and their families/caregivers
Mulatero C, Lal R, Jewitt K, Tolley C, Wells J, Arbuckle R, Lloyd A, Brazier J, Devlin N
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 18th Annual European Congress, Milan, Italy, 7-11 November 2015
Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with Nivolumab (NIVO)
Fallowfield L, Nadler E, Abernethy AP, Gilloteau I, Greaney M, Gater A, Orsini L, Subar M, Dastani HB, Lyman GH
Poster session presented at: European Cancer Congress, Vienna, Austria, 25-29 September 2015
Societal burden and impact on health related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) in Europe
Enstone A, Panter C, Manley Daumont M, Miles R
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 18th Annual European Congress, Milan, Italy, 7-11 November 2015
Systematic review of the caregiver burden in melanoma and renal cell carcinoma within Europe
Farrington E, Zagorska A, Burnett J
Poster session presented at the Society for Melanoma Research (SMR) 12th International Congress, San Francisco, USA, 2015
Use and usefulness of PRO endpoints in oncology trials
Shields AL
Invited session chair at the Drug Information Associations (DIA) meeting, Advancing the Science of Study Endpoints. Bethesda, MD USA
Patient-reported outcomes for US oncology labeling: Review and discussion of score interpretation and analysis methods
Shields AL, Coon C, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, Globe D
Expert Review of Pharmacoeconomics & Outcomes Research, 15(6), 951-959
A European study of the emotional and physical impact of relapse on patients with multiple myeloma
Hulin C, Hansen T, Laurenson S, Lawrence J, Streetly M
Poster session presented at: 19th Congress of the European Haematology Association, Milan, Italy, 12-15 June 2014
Qualitative assessment of multiple myeloma symptoms and health-related quality of life in relapsed/refractory patients and comparison to the EORTC QLQ-C30 and MY-20, FACT-MM, and MDASI-MM
Trask PC, Taylor F, Shields A, Mehta J, Foley C, Olude O, Lamoureux R, Iovin R, Hsu K
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual International Congress, Montréal, Canada, 1-3 June 2014
A qualitative assessment of symptoms and functional impact in relapsed/refractory multiple myeloma patients and comparison to the EORTC QLQ-C30 and MY-20, FACT-MM, and MDASI-MM
Trask P, Taylor F, Shields AL, Gallagher M, Mehta J, Foley C, Olude F, Lamoureux R, Iovin R
Poster presented at the 55th annual meeting of the American Society of Hematology, New Orleans, LA USA, 2013
Association of health-related quality of life and neurocognitive function with progression free survival and progressive disease in patients with glioblastoma: A review of the literature
Shields AL, Burgess S, Ravelo A, Taylor F, Mazar I, Abrey L
Poster presented at the 17th European Cancer Congress, Amsterdam, Netherlands, 2013
Disease state preference study in the UK general public for late-stage chronic lymphocytic leukaemia
Tolley K, Goad C, Yi Y, Maroudas P, Caravotas L, Thompson G
Eur J Health Econ 2013 Oct;14(5):749-59 [doi: 10.1007/s10198-012-0419-2. Epub 2012 Sep 1.]
PRO claims in Japanese oncology product labeling
Crawford B
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 16th Annual European Congress, Dublin, Ireland, 2-6 November 2013
Qualitative assessment of symptoms and functional impact in relapsed/refractory multiple myeloma patients and comparison to the EORTC QLQ-C30 and MY-20, FACT-MM, and MDASI-MM
Trask P, Taylor F, Shields A, Gallagher M, Mehta J, Foley C, Olude F, Lamoureux R, Iovin R, Hsu K
Poster session presented at 55th American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, 7-10 December 2013
Patient reported outcomes are changing the landscape in oncology care: Challenges and opportunities for the payer
Zagadailov E, Fine M, Shields AL
American Health & Drug Benefits, 6(5)
The effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial
Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun S, Sandor V, Levy RS, Kantarjian MN, and Verstovsek S on behalf of all COMFORT-I Investigators
Journal of Clinical Oncology, 31(10), 1285-1292
Use of the functional assessment of cancer therapy-anemia (FACT-AN) instrument in persons with MPN-associated myelofibrosis and anemia
Hudgens S, Gale RP, Tencer T, Khan Z
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 18th International Meeting, New Orleans, USA, 20 -22 May 2013
Utility and willingness to pay for lung cancer treatments: Patient versus general population values in Thailand
Thongprasert S, Permsuwan U, Sakulbumrungsil R, Chaiyakunapruk N, Crawford B, Petcharapiruch S, Leartsakulpanitch J
Poster session presented at: HTAi, Seoul Korea, 17–19 June 2013
The progressive burden of myelofibrosis in untreated patients: An assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Mesa RA, Shields AL, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S
Leukemia Research, 37(8), 911-916
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, Rea D
Leuk Res 2012 Jul;36(7):817-25
Content validity of a treatment satisfaction questionnaire in non-Hodgkin’s lymphoma
Campbell A, Wiesner C, Garcia EB, Tatlock S, Humphrey S
Value Health 2012;15;A480
Content validity of a treatment satisfaction questionnaire in non-Hodgkin’s lymphoma
Campbell A, Wiesner C, Garcia EB, Tatlock S, Humphrey S
Poster presented at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Berlin, Germany, 2012
Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis
Crawford B, Piault E, Gotlieb W, Joulain F
Patient Relat Outcome Meas 2012;3:21
Development of a patient-reported outcome instrument in brain metastases: The Brain Metastases Symptom and Impact Questionnaire (BASIQ)
Lasch KE, Ganguli A, Bonthapally V, Pompilus F, Delbecque L, Fitzgerald K, Ray S
Podium presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 17th Annual International Meeting, Washington, USA, 2-6 June 2012
Development of a patient-reported outcome instrument in brain metastases: The Brain Metastases Symptom and Impact Questionnaire (BASIQ)
Lasch KE, Ganguli A, Bonthapally V, Pompilus F, Delbecque L, Fitzgerald K, Ray S
Value Health 2012;15:A1
Evaluating meaningful change on the lung cancer symptom scale in small cell lung cancer: Results from a phase III clinical trial
O’Brien M, Hudgens S, King J, McNally R, Khan Z
Value Health 2012;15:A227
Evaluating meaningful change on the lung cancer symptom scale in small cell lung cancer: Results from a phase III clinical trial
O’Brien M, Hudgens S, King J, McNally R, Khan Z
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 17th Annual International Meeting, Washington, USA, 2-6 June 2012
Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study
Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J
Asia Pac J Clin Oncol 2012;8:282
Patient-Reported Outcomes (PROs) in antineoplastic product approvals in Europe and in the USA
Patrick D, Acquadro C, Teschendorf B, Emery MP, Caron M, Arnould B
Poster presented at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Berlin, Germany, 2012
Progressive worsening of patient-reported outcomes in untreated patients with myelofibrosis
Mesa R, Shields AL, Hare T, Erickson-Viitanen S, Sun W, Verstovsek S
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 17th Annual International Meeting, Washington, USA, 2-6 June 2012
Patient-Reported Outcomes (PROs) in antineoplastic product approvals in Europe and in the USA
Patrick D, Acquadro C, Teschendorf B, Emery MP, Caron M, Arnould B
Value Health 2012;15:A431
Review of the content validity of the patient-reported outcome measures used in patients with brain metastases
Fitzgerald K, Ganguli A, Bonthapally V, Pompilus F, Delbecque L, Lasch KE, Ray S
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 17th Annual International Meeting, Washington, USA, 2-6 June 2012
The progressive burden of myelofibrosis (MF) in untreated patients: An assessment of patient reported outcomes in placebo-treated patients from COMFORT-1
Mesa R, Shields AL, Hare T, Erickson-Viitanen S, Sun W, Verstovsek S
Poster presented at the 17th Congress of the European Hematology Association (EHA). Amsterdam, Netherlands, 2012
Use of the Functional Assessment of Cancer Therapy-Anemia (FACT-AN) instrument in persons with MPN-associated myelofibrosis and anemia
Hudgens S, Gale RP, Tencer T, Khan Z
Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 17th Annual International Meeting, Washington, USA, 2-6 June 2012
Women’s experiences of group cognitive behaviour therapy for hot flushes and night sweats following breast cancer treatment: an interpretative phenomenological analysis
Balabanovic J, Ayers B, Hunter MS
Maturitas 2012;72:236
Review of the content validity of the patient-reported outcome measures used in patients with brain metastases
Fitzgerald K, Ganguli A, Bonthapally V, Pompilus F, Delbecque L, Lasch KE, Ray S
Value Health 2012;15:227
Using primary patient data to identify the symptoms of brain metastases to develop a patient-reported outcome measure
Lasch KE, Fitzgerald K, Ganguli A, Bonthapally V, Pompilus F, Delbecque L, Ray S
J Clin Oncol 2012;30:e12515
An evaluation of statistical methods used to analyse patient-reported outcomes (PRO) data in published metastatic cancer studies
Gilet H, Brédart A, Regnault A, Bhandary D, Parasuraman B
Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Madrid, Spain, 2011
Associations between improvements in Myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: A randomized, double-blind, phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF
Mesa RA, Gotlib J, Gupta V, DiPersio J, Catalano J, Deininger M, Shields AL, Miller C, Silver R, Talpaz M, Winton E, Harvey J, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy R, Kantarjian H, and Verstovsek S on behalf of all COMFORT-I Investigators
Poster presented at the 53rd annual meeting of the American Society of Hematology. San Diego, CA, USA, 10-13 December 2011
Medico-economic analysis of the impact of malnutrition on the post-operative course of colorectal cancer patients
Preaud E, Melchior JC, Carles J, Brami M, Duru G, Fontaine E, Hébuterne X, Lukacs B, Zazzo JF, Panis Y, Nitenberg G
Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Madrid, Spain, 2011
Oncology patient-reported claims: Maximising the chance for success
Kitchen H, Rofail D, Caron M
Ecancermedicalscience 2011;5:212
Overview of primary endpoints, progression-free survival (PFS) and overall survival (OS) for non-small cell lung cancer (NSCLC): Their value in treatment decisions and patient care
Heron L, De Castro Carpeño J, Chouaid C, Vergnenègre A, Bischoff H G, Walzer S
Value Health 2011;14:A177
Pain in castration-resistant prostate cancer with bone metastases: A qualitative study
Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC
Health Qual Life Outcomes. 2011 Oct 12;9:88
Quality of life in small cell lung cancer: Results of an open-label phase III clinical trial
Hudgens S, King J, Khan ZM
Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Madrid, Spain, 2011
Results using the modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0) in COMFORT I: A randomized, double-blind phase III trial of JAK1/2 inhibitor ruxolitinib vs. placebo for patients with myelofibrosis (MF)
Mesa RA, Kantarjian H, Shields AL, Gotlib JR, Gupta V et al. on behalf of all COMFORT-1 investigators
Poster presented at the 16th Congress of the European Hematology Association. London, England, 9-12 June 2011
Quality of life in small cell lung cancer: Results of an open-label phase III clinical trial
Hudgens S
Value Health 2011;14:A460
Confirmation of Brief Pain Inventory Short Form (BPI-SF) ‘worst pain’ item cut-point for the assessment of pain progression in castration-resistant prostate cancer (CRPC)
Regnault A, Gater A, Battersby C, Meunier J, Abetz L
Value Health 2010;13:A274
Confirmation of Brief Pain Inventory Short Form (BPI-SF) ‘worst pain’ item cut-point for the assessment of pain progression in castration-resistant prostate cancer (CRPC)
Regnault A, Gater A, Battersby C, Meunier J, Abetz L
Poster presented at ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic
Mixed treatment comparison of bevacizumab-based therapies relative to doublet-chemotherapy combinations to estimate the relative efficacy in progression-free survival for treatment of first-line advanced or metastatic non-small cell lung cancer (NSCLC)
Yi Y, Chouaid C, Vergnenegre A, Bischoff HG, Bergman G, Walzer S, Philips Z
Value in Health 2010; 13 (7): A253-A254
Mixed treatment comparison of bevacizumab-based therapies relative to doublet-chemotherapy combinations to estimate the relative efficacy in progression-free survival for treatment of first-line advanced or metastatic non-small cell lung cancer (NSCLC)
Yi Y, Chouaid C, Vergnenegre A, Bischoff HG, Bergman G, Walzer S, Philips Z
Poster presented at ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic
Drivers of treatment decision following first-line therapy in advanced non-small cell lung cancer
Lasch K, Stokes J, Liepa A, Meldahl M, Arnett L, Basch E
Support Care Cancer 2010; 18:S88
Results of the patient-reported outcomes of fatigue in cancer consortium study: patients define cancer-related fatigue
Lasch K, Marquis P, Zeytoonjian A, Yaworsky A, Leonard C, Patient-Reported Outcomes in Fatigue (PROOF) consortium
Poster session presented at: 2nd International Cancer Fatigue Symposium, Montreal, Canada, 3–4 October 2010
Utility elicitation study in the UK general public for late stage chronic lymphocytic leukaemia
Tolley K, Goad C, Yi Y, Maroudas P, Thompson G
Poster presented at ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic
Evaluation of the willingness-to-pay for anticancer treatment among Korean patients with metastatic breast cancer: a multicenter, cross-sectional study
Lee S, Oh D, Kim S, Chung HC, Ko SK, Crawford B, McDonald J, Ro J
J Clin Oncol 2010;28:e11517
Evaluation of the willingness-to-pay for anti-cancer treatment amongst Korean metastatic breast cancer patients: A multicenter, cross-sectional study
Oh DY, Kim SB, Chung HC, Lee SY, Ko SK, Crawford B, McDonald J, Ro J
Poster session presented at: Korean Association for Clinical Oncology, Seoul, Korea, 21 November 2009
Oncology patient-reported claims: maximising the chance for success
Rofail D, Abetz L, Caron M, Emery MP, Kitchen H
Value Health 2009;12:A283